Please login to the form below

Not currently logged in
Email:
Password:

Still's disease

This page shows the latest Still's disease news and features for those working in and with pharma, biotech and healthcare.

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

to-treat disease.”. ... AZ and Merck’s drug is still in front in terms of sales, bringing in $218m last year, compared to $109m for Zejula and $55m for Rubraca.

Latest news

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia

  • Another Alzheimer's bust as Merck & Co stops verubecestat study Another Alzheimer's bust as Merck & Co stops verubecestat study

    Merck Research Laboratories president Roger Perlmutter said the company is "disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer's disease.".

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... around 2, 500 people in

  • Lilly closes Avid buy

    Lilly has made major investments in the Alzheimer's disease space, with several key treatments still in development in spite of the recent failure of its late-stage product candidate semagacestat. . ... other diseases, including Parkinson's disease and

  • Lifting the fog

    Despite numerous setbacks, the hunt for an Alzheimer's disease cure is still ongoing. ... The debilitating neurological condition Alzheimer's disease (AD) affects one in ten people over 65 years of age and half of people over 85.

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics